Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, health care giant Abbott Laboratories (ABT 0.82%) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at Abbott and see what CAPS investors are saying about the stock right now.
Abbott facts
|
Headquarters (founded) |
Abbott Park, Ill. (1888) |
|
Market Cap |
$55.2 billion |
|
Industry |
Healthcare equipment |
|
Trailing-12-Month Revenue |
$40.0 billion |
|
Management |
Chairman/CEO Miles White (since 1999) |
|
Return on Equity (average, past 3 years) |
20.6% |
|
Cash / Debt |
$8.5 billion / $7.1 billion |
|
Dividend Yield |
1.6% |
|
Competitors |
Boston Scientific |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 97% of the 2,606 members who have rated Abbott believe the stock will outperform the S&P 500 going forward.
Just last week, one of those Fools, All-Star healthcarevalue, brought Abbott's solid fundamentals to our community's attention:
Price/earnings good at 10.4, reasonable market cap, Return on Invested Capital (ROIC) [13.18%] last twelve trailing months, ROIC of over [10%] going back to 2007, Low debt/equity ratio of 0.15. Abbott Laboratories has 91,000 employees and strong value in both its generic drug segment and diagnostic segments.
